AR109135A2 - Forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina inhibidor de dpp-iv - Google Patents

Forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina inhibidor de dpp-iv

Info

Publication number
AR109135A2
AR109135A2 ARP170102064A ARP170102064A AR109135A2 AR 109135 A2 AR109135 A2 AR 109135A2 AR P170102064 A ARP170102064 A AR P170102064A AR P170102064 A ARP170102064 A AR P170102064A AR 109135 A2 AR109135 A2 AR 109135A2
Authority
AR
Argentina
Prior art keywords
solid form
compound
pirrolidine
dpp
inhibiting
Prior art date
Application number
ARP170102064A
Other languages
English (en)
Inventor
Julie M Cherrington
David Alan Campbell
Zhen-Ping Wu
Original Assignee
Phenomix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomix Corp filed Critical Phenomix Corp
Publication of AR109135A2 publication Critical patent/AR109135A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina, caracterizada porque el compuesto de pirrolidina tiene la fórmula (1) o una forma cíclica de la misma, de fórmula (2), o una mezcla de las mismas, donde la forma sólida comprende entre 8 y 14% en peso de agua y es sustancialmente no higroscópica cuando se la expone a la atmósfera a una humedad relativa de hasta entre 40 y 60% a 25ºC.
ARP170102064A 2006-08-30 2017-07-21 Forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina inhibidor de dpp-iv AR109135A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84109706P 2006-08-30 2006-08-30

Publications (1)

Publication Number Publication Date
AR109135A2 true AR109135A2 (es) 2018-10-31

Family

ID=39136484

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070103842A AR062590A1 (es) 2006-08-30 2007-08-29 Sales solidas de citrato y tartrato de inhibidores de dpp-iv, preparacion de las mismas, una composicion y una combinacion farmaceutica que las comprenden y el uso de las mismas en trastornos del control de la glucemia.
ARP170102064A AR109135A2 (es) 2006-08-30 2017-07-21 Forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina inhibidor de dpp-iv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP070103842A AR062590A1 (es) 2006-08-30 2007-08-29 Sales solidas de citrato y tartrato de inhibidores de dpp-iv, preparacion de las mismas, una composicion y una combinacion farmaceutica que las comprenden y el uso de las mismas en trastornos del control de la glucemia.

Country Status (18)

Country Link
US (1) US8299271B2 (es)
EP (1) EP2061474A4 (es)
JP (1) JP5264728B2 (es)
KR (1) KR101504769B1 (es)
CN (1) CN101522201B (es)
AR (2) AR062590A1 (es)
AU (1) AU2007290684B2 (es)
BR (1) BRPI0715447B8 (es)
CA (1) CA2661776C (es)
CL (1) CL2007002499A1 (es)
EA (1) EA017833B1 (es)
HK (1) HK1134248A1 (es)
IL (2) IL197225A (es)
MX (1) MX2009002281A (es)
NO (1) NO20091291L (es)
TW (1) TW200817324A (es)
WO (1) WO2008027273A2 (es)
ZA (1) ZA200901510B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002499A1 (es) 2006-08-30 2008-03-14 Phenomix Corp Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2730580A1 (en) * 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EP2326326B1 (en) 2008-08-15 2019-10-09 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
CN117547538A (zh) 2009-02-13 2024-02-13 勃林格殷格翰国际有限公司 包含dpp-4抑制剂(利格列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102286011B (zh) * 2010-03-16 2017-10-03 美德（江西）生物科技有限公司 吡咯烷硼酸酯二肽基肽酶抑制剂及其药物组合物
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
EP2556056A1 (en) 2010-04-06 2013-02-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US20130289049A1 (en) * 2010-08-05 2013-10-31 Boehringer Ingelheim International Gmbh Acid addition salts of the 2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-(methyl)amino]ethoxy]-n-methyl-n-[3-(4-methylpiperazin-1-yl)cyclohexyl] acetamide and the use thereof as bradykinin b1 receptorantagonists
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103483363B (zh) * 2012-06-13 2016-12-21 上海赛迦化工产品有限公司 多样性的手性氨基硼酸及其制备方法和应用
IN2015DN03795A (es) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
JP2014129255A (ja) * 2012-12-28 2014-07-10 Fujifilm Corp 組成物およびフィルムならびにそれらの製造方法
EP3145526A1 (en) 2014-05-20 2017-03-29 Millennium Pharmaceuticals, Inc. Boron-containing proteasome inhibitors for use after primary cancer therapy
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
KR101978364B1 (ko) 2017-06-15 2019-05-14 크리스탈지노믹스(주) 알킬카바모일 나프탈렌일옥시 옥테노일 하이드록시아마이드 또는 그 유도체의 약학적으로 허용 가능한 염 및 그 제조방법
CN111537622B (zh) * 2019-11-29 2021-11-26 杭州华东医药集团新药研究院有限公司 一种度格列汀及其盐的杂质的检测方法
CN111533675B (zh) * 2019-11-29 2021-09-28 杭州华东医药集团新药研究院有限公司 杂环硼酸化合物的杂质及其控制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109681A2 (en) * 2007-03-08 2008-09-12 Phenomix Corporation Methods and intermediates for synthesis of selective dpp-iv inhibitors
EP1743676A1 (en) 2003-11-12 2007-01-17 Phenomix Corporation Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2617310A1 (en) * 2005-08-01 2007-02-08 Phenomix Corporation Methods of preparing hetercyclic boronic acids and derivatives thereof
CL2007002499A1 (es) 2006-08-30 2008-03-14 Phenomix Corp Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
PE20080668A1 (es) 2006-08-30 2008-07-17 Novartis Ag Compuestos heterociclicos como inhibidores de la cinasa-2 de proteina activada por cinasa de proteina activada por mitogeno
JP5128599B2 (ja) 2006-08-30 2013-01-23 エフ．ホフマン−ラ ロシュ アーゲー Ｇｌｙｔ−１の阻害薬
CL2007002513A1 (es) 2006-08-30 2008-04-04 Celgene Corp Soc Organizada Ba Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.

Also Published As

Publication number Publication date
AU2007290684B2 (en) 2012-08-16
AR062590A1 (es) 2008-11-19
NO20091291L (no) 2009-03-27
WO2008027273A3 (en) 2008-07-31
IL197225A (en) 2015-11-30
EA017833B1 (ru) 2013-03-29
BRPI0715447B8 (pt) 2021-05-25
CA2661776C (en) 2015-03-24
AU2007290684A1 (en) 2008-03-06
EP2061474A4 (en) 2011-06-15
TW200817324A (en) 2008-04-16
MX2009002281A (es) 2009-05-20
KR101504769B1 (ko) 2015-03-20
IL197225A0 (en) 2009-12-24
EA200900375A1 (ru) 2009-10-30
HK1134248A1 (zh) 2010-04-23
CA2661776A1 (en) 2008-03-06
JP5264728B2 (ja) 2013-08-14
CN101522201A (zh) 2009-09-02
EP2061474A2 (en) 2009-05-27
KR20090043601A (ko) 2009-05-06
WO2008027273A2 (en) 2008-03-06
BRPI0715447A2 (pt) 2014-05-06
CL2007002499A1 (es) 2008-03-14
US20100323988A1 (en) 2010-12-23
IL242267A (en) 2017-12-31
JP2010502610A (ja) 2010-01-28
CN101522201B (zh) 2015-08-19
BRPI0715447B1 (pt) 2020-09-15
US8299271B2 (en) 2012-10-30
ZA200901510B (en) 2010-05-26
IL242267A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
AR109135A2 (es) Forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina inhibidor de dpp-iv
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
EA201070786A1 (ru) Бензофуропиримидиноны
HRP20120323T1 (en) Diarylhydantoin compounds
DE602005008996D1 (de) Radiofluorierte peptide
SMAP200900013A (it) Peptidomimetici smac utili come inibitori di iap
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CO6612278A2 (es) Composición acuosa antitranspirante/desodorante
ECSP066893A (es) Inhibidores de proteínas de apoptosis (iap)
CY1114793T1 (el) Παραγωγα αμινοπυραζολιου
PA8683501A1 (es) Derivados de isoquinolina
CY1113011T1 (el) Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην
ATE459622T1 (de) Tropanverbindungen
ECSP077130A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de náuseas y vómitos
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
AR052853A1 (es) Composiciones orales que contienen compuestos antibacterianos de bifenol
ES2421447T3 (es) Métodos para proteger frente a apoptosis usando lipopéptidos
AR061134A1 (es) Derivados de tioxantina
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
UY29169A1 (es) Derivados de 2-amido-4 feniltiazol, su preparacion y su aplicacion en terapeutica
MEP10209A (en) Stable emulsion composition
NO20085317L (no) Imidazoazepinonforbindelser
UY30788A1 (es) Compuestos quimicos
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
CR9565A (es) Derivados del 4,5-diarilpirrol, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure